Acute allograft rejection remains a significant problem in transplantation, undermining the function and survival of grafts transplanted to treat end-stage organ disease. Acute rejection is mediated by the coordinated infiltration and effector functions of alloantigen-primed T cells resulting in destruction of the graft tissue. Factors directing T cells into organ allografts remain poorly defined. Our studies have demonstrated the temporal induction of chemoattractant cytokines, chemokines, in skin and heart allografts during the progression of acute rejection. At the time of acute rejection in these models as well as in biopsies from clinical heart transplants, high levels of several chemokines are present, including the IFN-gamma induced chemokine Mig a potent T cell chemoattractant. Administration of Mig-specific antibodies inhibits T cells infiltration into skin allografts and promotes long-term graft survival supporting the use of this strategy in transplantation. Our preliminary studies using a heart allograft model have indicated that recipient treatment with Mig-specific antibodies delays both T cell infiltration and acute rejection of the grafts, however, the grafts are eventually rejected. This delayed rejection is not mediated through Mig directed recruitment of T cells into the allograft. In this application we will test the induction and role of chemokine receptors that direct alloantigen-primed T cell infiltration into cardiac allografts and the role of the T cell chemoattractant Mig during acute rejection of vascularized heart allografts using a murine model.
In Specific Aim 1 we will test the temporal expression of chemokine receptors on individual and identifiable alloantigen-specific T cell populations during priming to cardiac allografts.
Specific Aim 2 will test the role of these receptors in directing the alloantigen-primed CD4+ and CD8+ T cells into allografts using receptor deficient mice as recipients.
Specific Aim 3 will test the role of Mig in directing alloantigen-primed T cells into the allografts.
Specific Aim 4 will test potential mechanisms mediating the delayed rejection of heart allografts in recipients treated with Mig-specific antibodies. Understanding the role of these receptors and Mig in acute rejection will elucidate mechanisms of T cell recruitment into allografts during acute rejection. The results should support the development of novel therapeutic reagents and strategies to inhibit T cell recruitment into allografts, improving solid organ allograft survival while decreasing the dependence on the generalized and debilitating immunosuppressive regimens currently in use.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI051620-01A1
Application #
6630853
Study Section
Special Emphasis Panel (ZRG1-SSS-W (01))
Program Officer
Kehn, Patricia J
Project Start
2003-04-01
Project End
2004-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
1
Fiscal Year
2003
Total Cost
$335,250
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
017730458
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Rosenblum, Joshua M; Shimoda, Naohiko; Schenk, Austin D et al. (2010) CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J Immunol 184:3450-60
Wehner, Jennifer R; Morrell, Craig N; Rodriguez, E Rene et al. (2009) Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions. J Clin Immunol 29:722-9
Schenk, A D; Gorbacheva, V; Rabant, M et al. (2009) Effector functions of donor-reactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts. Am J Transplant 9:64-73
Fukuzawa, Nobuyuki; Schenk, Austin D; Petro, Marianne et al. (2009) High renal ischemia temperature increases neutrophil chemoattractant production and tissue injury during reperfusion without an identifiable role for CD4 T cells in the injury. Transpl Immunol 22:62-71
Rosenblum, Joshua M; Zhang, Qi-Wei; Siu, Gerald et al. (2009) CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival. Transplantation 87:360-9
Schenk, Austin D; Rosenblum, Joshua M; Fairchild, Robert L (2008) Chemokine-directed strategies to attenuate allograft rejection. Clin Lab Med 28:441-54, vii
Bickerstaff, A; Nozaki, T; Wang, J-J et al. (2008) Acute humoral rejection of renal allografts in CCR5(-/-) recipients. Am J Transplant 8:557-66
Nozaki, Taiji; Rosenblum, Joshua M; Ishii, Daisuke et al. (2008) CD4 T cell-mediated rejection of cardiac allografts in B cell-deficient mice. J Immunol 181:5257-63
Nozaki, Taiji; Amano, Hiroyuki; Bickerstaff, Alice et al. (2007) Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 179:5238-45
Shimoda, Naohiko; Fukazawa, Nobuyuki; Nonomura, Katsuya et al. (2007) Cathepsin g is required for sustained inflammation and tissue injury after reperfusion of ischemic kidneys. Am J Pathol 170:930-40